ESWT on Human Gingival Fibroblasts

The idea of treating different deformities or diseases in the maxillofacial region with Extracorporeal Shockwave Therapy (ESWT) has recently become popular. Shockwave therapy was first introduced in Germany in 1980s and has been widely used in medical practice for the management of urolithiasis, cholelithiasis and in head and neck region for sialolithiasis.

The present study 'Application of Extracorporeal Shock Wave Therapy on human gingival derived fibroblasts In-vitro study' was done to explore and evaluate the effect of shockwaves. Further, these cells were assessed for Cell - Cell interaction and Cell Viability.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Periodontal Attachment Loss Hyperplasia Mouth Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Periodontal Atrophy Periodontal Diseases Stomatognathic Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Krishnadevaraya College of Dental Science and Hospital

Bengaluru, Karnataka, 562157, India

About this study

BACKGROUND:

Improved understanding of human biology at the molecular level, scientific and technologic advances are emerging aspects in dentistry. The idea of treating different deformities or diseases in the maxillofacial region with Extracorporeal Shockwave Therapy (ESWT) has recently become popular. Shockwave therapy was first introduced in Germany in 1980s and has been widely used in medical practice for the management of urolithiasis, cholelithiasis and in head and neck region for sialolithiasis.

AIM:

The present study 'Application of Extracorporeal Shock Wave Therapy on human gingival tissue derived fibroblasts In-vitro study' was done to explore and evaluate the effect of shockwaves. Further, fibroblast cells were assessed for Cell - Cell interaction and Cell Viability.

MATERIALS AND METHODS:

In this in-vitro study, 20 fibroblast cells were included. 10 samples were considered for Control group and the remaining 10 samples were considered as Test group. Extracorporeal shockwave was applied to the Test samples. They were further analysed using wound scratch assay which was used to assess Cell proliferative rate and scratch closure through live imaging. MTT assay and ATP assay was used to determine Cell viability after exposure to shockwaves.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Viable human gingival fibroblast
Healthy gingival tissue

Exclusion criteria

contaminated samples

Treatment and study plan

Extracorporeal shockwave device

Device

Fibroblast cell lines (n=10) were subjected to Shockwaves from extracorporeal shockwave device

Fibroblast cell lines not subjected to shockwaves from extracorporeal shockwave device

Other

Fibroblast cell lines (n=10) without shockwave exposure

Primary outcomes

Fibroblast cell lines exposed to shockwave from extracorporeal shockwave device

Time frame: 74 hrs

Cell proliferation and Cell viability

Sponsors and collaborators

Lead sponsor

Dr Prabhuji MLV

Other

Registry information

Official study title

Application of Extracorporeal Shockwaves on Human Gingival Fibroblasts in Vitro Study

Acronym: ESWT

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2023
First posted: Mar 13, 2023
Registry last updated: Mar 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed